HIV/Aids experts says American recommendation is `immoral’
Activists in Uganda, where some 400 people are infected with HIV every day, have called on the government to rethink its dismissal of an emerging prevention protocol demonstrated to be effective in a trial conducted partly in Uganda, and which has been approved by the US Food and Drug Administration.
The protocol in question is a form of pre-exposure prophylaxis (PrEP) involving a daily dose of two antiretroviral drugs - marketed as Truvada - taken by an uninfected person who is in a sexual relationship with an HIV-positive partner.
According to PrEPWatch, a website run by AVAC (Global Advocacy for HIV Prevention), Truvada “has been proven effective at reducing the risk of HIV via sexual exposure in heterosexual men and women, gay men and other men who have sex with men, and transgender women”. One study among serodiscordant couples in Kenya and Uganda, found Truvada reduced HIV transmission by 73 percent, when compared against a placebo.